Clinical characteristics of 41 patients with head and neck squamous cell carcinoma (received concurrent cetuximab and nivolumab) profiled with peripheral blood mononuclear cells immunosequencing
| Overall (N=41) | |
| Age on study | |
| Mean (SD) | 61.6 (11.3) |
| Median (min, max) | 64.0 (24.0, 78.0) |
| Gender | |
| Female | 8 (19.5%) |
| Male | 33 (80.5%) |
| Race | |
| Asian | 1 (2.4%) |
| Black or African American | 2 (4.9%) |
| White | 37 (90.2%) |
| Unknown | 1 (2.4%) |
| Primary site | |
| Hypopharynx | 1 (2.4%) |
| Larynx | 3 (7.3%) |
| Oral cavity | 13 (31.7%) |
| Oropharynx | 23 (56.1%) |
| Unknown primary | 1 (2.4%) |
| p16 status | |
| Negative | 18 (43.9%) |
| Positive | 23 (56.1%) |
| Smoking history | |
| Current smoker | 4 (9.8%) |
| Previous smoker | 21 (51.2%) |
| Never smoked | 16 (39.0%) |
| ECOG PS | |
| 0 | 14 (34.1%) |
| 1 | 25 (61.0%) |
| 2 | 2 (4.9%) |
| Prior immunotherapy | |
| No | 24 (58.5%) |
| Yes | 17 (41.5%) |
| Best response | |
| Complete response | 3 (7.3%) |
| Partial response | 6 (14.6%) |
| Stable disease | 20 (48.8%) |
| Progressive disease | 10 (24.4%) |
| Not assessed | 2 (4.9%) |
| Survival status | |
| Alive | 14 (34.1%) |
| Death | 27 (65.9%) |
ECOG PS, Eastern Cooperative Oncology Group Performance Status.